I’m so excited today! Everyone who joined my WhatsApp group has made money! If you haven’t joined yet, you can sign up for free today! (Limited to 30 spots) 🚀🚀
You can find the WhatsApp link in my bio! 👆🏻👆🏻👆🏻
Once you’ve joined the group, just reply with the number "9," and I’ll approve your request. Inside, we share real-time updates, discuss daily holdings, and adjust our strategies as needed—all to help you maximize your gains.
🚨 $INHD is back on the radar!
Inno Holdings saw its share price surge following the disclosure of a merger agreement that includes relocating the company’s jurisdiction of incorporation from Texas to the British Virgin Islands.
This move has sparked speculation regarding the company’s corporate structure and future market strategy. However, it is important to view this objectively: it is a restructuring transaction—not a premium resulting from an acquisition—nor does it necessarily signal a definitive new catalyst for growth.
Given the company’s small market capitalization, weak profitability, and the potential risk of equity dilution, share price volatility is likely to remain high. I will be closely monitoring SEC filings, shareholder approval status, and trading volume to gauge the direction of future developments. 📊
If you haven't added me as a Whatsapp contact, don't worry, I will share the Whatsapp link to you later.
I will share and discuss stock trading tips and profit knowledge with my fans on Whatsapp for free.
Please turn on notifications to avoid missing out
Fantastic! $NCPL has surged from $3.20 to $3.90—an increase of nearly 22%! 🚀📈
This is precisely why being prepared in advance and nailing your entry timing is so crucial. Members of my WhatsApp group get early access to my market research, trade setups, and potential investment opportunities—well before the general public.
🚨 $NCPL — This could represent a high-volatility reversal opportunity, but it comes with equally significant risks.
The compliance grace period granted by Nasdaq has eased short-term pressure regarding the company’s listing status, while a recent pickup in trading momentum has brought the stock back onto traders' radars.
However, the core issues remain: the company must resolve audit-related concerns, address allegations brought by the U.S. Securities and Exchange Commission (SEC), and rebuild market confidence in its financial reporting.
I will not be chasing this rally blindly. My focus is on whether a credible audit firm steps in, whether the financial statements prove reliable, and whether trading volume can show sustained growth.
The true catalyst is not another surge in the share price, but the restoration of the company’s credibility. ⚠️📊
My WhatsApp link:
👉 https://t.co/3KuHwXOcnG
After adding me, please send the number "9" via WhatsApp; I’ll then send you an invitation along with all the information you need to get started.
Fantastic! I bought $MRKR at $0.90, and it has now climbed to $1.39—a gain of nearly 58%! Patience and firm conviction are truly the keys to success. 🚀📈 Did anyone else catch this move? If you’re in my WhatsApp group, you would have received a precise buy signal well in advance. If you haven’t seen the detailed investment strategy I shared yet, come join my WhatsApp group—I’ll be waiting for you there. Let’s make sure everyone who follows me makes money!
🚨 $MRKR | A $16.2 Million Catalyst—But Execution Remains Key
Marker Therapeutics has just secured a $16.2 million non-dilutive grant from CPRIT to advance its core clinical program, MT-601, through the Phase II APOLLO study—targeting large B-cell lymphoma that has relapsed following CAR-T therapy.
This serves as a significant validation of the company’s lead clinical program and provides a substantial infusion of capital.
However, investors should maintain a balanced perspective:
• While early clinical data are encouraging, they are based on a small patient sample size.
• As of September 30, the company held $9.4 million in cash.
• Management anticipates that existing funds will be sufficient to sustain operations through the second quarter of 2027, without the need for additional financing.
• Future capital requirements—and the potential for equity dilution—remain key risks.
**My Take:** This is an important catalyst, but it does not guarantee a "turnaround" for the company. Keep a close eye on clinical execution, the disbursement schedule of the grant funds, cash runway, and trading volume.
Cut through the noise, conduct your own research, and make smarter decisions.
#MRKR #biotech #BiotechStocks #ClinicalTrials
My WhatsApp number:
☎️ +13072208130
After adding me as a contact, please send the number "9" via WhatsApp; I will then send you an invitation along with all the information you need.
I’m so excited today! Everyone who joined my WhatsApp group has made money! If you haven’t joined yet, you can sign up for free today! (Limited to 30 spots) 🚀🚀
You can find the WhatsApp link in my bio! 👆🏻👆🏻👆🏻
Once you’ve joined the group, just reply with the number "9," and I’ll approve your request. Inside, we share real-time updates, discuss daily holdings, and adjust our strategies as needed—all to help you maximize your gains.
🚨 $INHD is back on the radar!
Inno Holdings saw its share price surge following the disclosure of a merger agreement that includes relocating the company’s jurisdiction of incorporation from Texas to the British Virgin Islands.
This move has sparked speculation regarding the company’s corporate structure and future market strategy. However, it is important to view this objectively: it is a restructuring transaction—not a premium resulting from an acquisition—nor does it necessarily signal a definitive new catalyst for growth.
Given the company’s small market capitalization, weak profitability, and the potential risk of equity dilution, share price volatility is likely to remain high. I will be closely monitoring SEC filings, shareholder approval status, and trading volume to gauge the direction of future developments. 📊
Thank you for your support and interest!
I have set up a private WhatsApp group where I share carefully curated stock recommendations, daily trading updates, and the latest market insights.
👉 https://t.co/uaiRfIhl05
Once you join the group, you will have real-time access to all of this content.
Click the link to join for free (available for a limited time). I look forward to seeing you there!
🚨 $MRKR | A $16.2 Million Catalyst—But Execution Remains Key
Marker Therapeutics has just secured a $16.2 million non-dilutive grant from CPRIT to advance its core clinical program, MT-601, through the Phase II APOLLO study—targeting large B-cell lymphoma that has relapsed following CAR-T therapy.
This serves as a significant validation of the company’s lead clinical program and provides a substantial infusion of capital.
However, investors should maintain a balanced perspective:
• While early clinical data are encouraging, they are based on a small patient sample size.
• As of September 30, the company held $9.4 million in cash.
• Management anticipates that existing funds will be sufficient to sustain operations through the second quarter of 2027, without the need for additional financing.
• Future capital requirements—and the potential for equity dilution—remain key risks.
**My Take:** This is an important catalyst, but it does not guarantee a "turnaround" for the company. Keep a close eye on clinical execution, the disbursement schedule of the grant funds, cash runway, and trading volume.
Cut through the noise, conduct your own research, and make smarter decisions.
#MRKR #biotech #BiotechStocks #ClinicalTrials
🚨 $NCPL — This could represent a high-volatility reversal opportunity, but it comes with equally significant risks.
The compliance grace period granted by Nasdaq has eased short-term pressure regarding the company’s listing status, while a recent pickup in trading momentum has brought the stock back onto traders' radars.
However, the core issues remain: the company must resolve audit-related concerns, address allegations brought by the U.S. Securities and Exchange Commission (SEC), and rebuild market confidence in its financial reporting.
I will not be chasing this rally blindly. My focus is on whether a credible audit firm steps in, whether the financial statements prove reliable, and whether trading volume can show sustained growth.
The true catalyst is not another surge in the share price, but the restoration of the company’s credibility. ⚠️📊
🚨 $EJH is worth adding to your watchlist!
E-Home is expanding into the "AI-driven home services" sector with its new line of service robots, targeting markets such as in-home care, elderly care, and smart communities in China.
The "AI" narrative may attract momentum traders, and the company’s recent $43 million private placement adds an interesting dimension to its financial outlook.
However, proceed with caution: the company’s profitability remains weak, free cash flow is negative, and there is a significant risk of equity dilution.
Before concluding that a genuine "turnaround" is underway, I will be keeping a close eye on actual AI-related orders, revenue growth, and the sustainability of cash flow. Small-cap stocks are highly volatile—they can offer opportunities, but they also come with substantial risks. 📊
🚨 $INHD is back on the radar!
Inno Holdings saw its share price surge following the disclosure of a merger agreement that includes relocating the company’s jurisdiction of incorporation from Texas to the British Virgin Islands.
This move has sparked speculation regarding the company’s corporate structure and future market strategy. However, it is important to view this objectively: it is a restructuring transaction—not a premium resulting from an acquisition—nor does it necessarily signal a definitive new catalyst for growth.
Given the company’s small market capitalization, weak profitability, and the potential risk of equity dilution, share price volatility is likely to remain high. I will be closely monitoring SEC filings, shareholder approval status, and trading volume to gauge the direction of future developments. 📊
🚨 $SEAT has just announced a major recapitalization plan, which could mark a significant turning point in the evolution of Vivid Seats.
The company intends to reduce its net debt by approximately $232 million, secure $66 million in new financing, and extend the maturity date of its loans to 2032.
This move represents a major step toward easing pressure on the balance sheet. However, there is a catch: upon completion of the transaction, the newly issued shares could account for roughly 80% of the common equity.
This is a high-stakes "turnaround" play. While the reduction in debt is a positive development, the substantial dilution of shareholder equity cannot be overlooked. I will be keeping a close eye on the final closing of the deal, trading volume, and cash flow performance. 📊
On the eve of Anthropic's IPO, the stock prices of related beneficiary targets rose
Here are some market market movements: Amazon (265.127.23, 2.80%, ) (AMZN), Google (278.3550.76, 0.27%, ) (GOOGL) shares rose by 2% and nearly 1%, respectively. Both companies have made independent investments in Anthropic and are directly related beneficiaries of Anthropic. In April this year, Amazon agreed to invest up to $25 billion in Anthropic. In the same month, Google announced plans to invest up to $40 billion in Anthropic to further deepen their long-term partnership.
Broadcom (AVGO) shares surged nearly 3%. This chip manufacturer is a core partner of Anthropic; Previously, both parties announced the establishment of a Special Purpose Vehicle (SPV), with related equipment to be leased to Anthropic for use.
$SLS $GP $FRTT $MPU
Consecutive outages in tech systems triggered panic stockpiling among the public, benefiting Costco
On October 2, 2026, in Bayonne, New Jersey, a customer pushed a shopping cart full of goods out of a Costco warehouse supermarket.
A series of technology system outages have prompted consumers to purchase large quantities of emergency supplies. According to data from Mizuho Securities Research Institute, Costco's sales have been boosted as a result.
Mizuho estimates that in the last week of October, Costco's same-store sales in the U.S. (excluding gasoline) will increase by 11%-12% year-on-year; The normal increase in the first three weeks of October was only 6%-7%. Costco reported an overall same-store sales growth of 8.1% in October. Institutions stated that the strong sales growth trend continued into November; As of Sunday evening, among the 26 high-priced generators tracked by Ruiho on Costco's official website, 21 had already sold out.
On Wednesday morning, Costco's stock price was roughly flat and slightly weaker, around $1,107 per share.
Mizuho analyst David Bellinger wrote in a Monday report: "Microsoft (503.49-2.75, -0.54%, ) Outlook crashes, total suspension of US airlines, and the spread of doomsday panic on social media, Multiple factors have driven up Costco's emergency reserve sales volume. ”
This wave of stockpiling was triggered by a series of major system failures: Microsoft Outlook and Teams service outages on Thursday; On Friday, the U.S. Federal Aviation Administration ordered all flights in the U.S. to be banned from taking off; On Monday, JPMorgan Chase (326.43-3.53, -1.07%, ) experienced a software failure causing delays in banking transactions, and on the same day, United Airlines experienced a system outage causing flight delays; On Tuesday, the NSA confirmed a brief outage in its communications network.
The multiple outages have erupted in a concentrated manner due to various parties urgently fixing software vulnerabilities found by AI tools. Government officials have stated that the public need not panic.
But on social platforms like TikTok, posts urging people to stockpile food and various supplies have gained extremely high attention.
Mizuho raised Costco's target price from $1,100 to $1,150, maintaining an equivalent "outperform" rating of buy. Institutions predict that same-store sales growth in the U.S. in November may exceed 10%.
Mizuho also pointed out that Sam's Club, owned by Walmart (126.265-1.25, -0.98%, ), also benefited from the rush to buy emergency supplies, with consumers purchasing large quantities of food in reserve; Home Depot (336.155-2.85, -0.84%, )%) and Lloyd's benefited from people purchasing emergency home renovation supplies.
This warehouse retailer will release its financial report for the first quarter of fiscal year 2027 on December 10, and Mizuho will focus on whether this sales surge will drive an increase in new membership.
📊 $HIHO — This is more than just a short-term speculative play!
Highway Holdings Limited has just reported a significant operational turnaround.
In the second quarter, revenue surged 107% year-over-year to $2.44 million, while gross profit jumped by 201%. The gross margin expanded to 37.2%, and the company has returned to operating profitability.
Even more noteworthy are the improvements in operating leverage, the recent completion of a $7 million strategic investment, a proposed spin-off of the manufacturing business, and plans to distribute cash dividends to shareholders.
I am particularly focused on whether these higher margins and operating profitability can be sustained into the next quarter. This is a "turnaround" story worth watching closely—though consistent, stable earnings and cash flow will be the ultimate litmus test. 📈
🤖 $GMM — A connection to Anthropic puts AI back in the spotlight!
Global Mofy (GMM) recently disclosed an indirect investment in Anthropic via an investment fund, adding a new dimension to its AI strategy.
What’s noteworthy is the company’s integration of cutting-edge AI positioning, digital asset technology, a generative 3D platform, and potential enterprise-grade applications.
However, investors should distinguish between "indirect investment exposure" and "direct ownership." The ultimate economic value will depend on the fund's structure and whether GMM can successfully commercialize its own AI business.
I’ll be keeping a close eye on improvements in transparency, revenue growth, and the sustainability of market buying interest. While the push into AI is exciting, execution and valuation remain critical. 🚀
🤖 $INLF— Industrial Robotics Moves Toward Commercial Deployment!
INLF has just announced sales agreements with 10 industry partners, with a total estimated value exceeding $10 million. More importantly, the company has already received partial advance payments, with deliveries scheduled to begin in January 2027.
This marks a substantial step forward for the company—shifting from mere "strategic statements" to tangible progress. The key catalyst moving forward is "execution": can the company effectively translate these agreements into actual deliveries, recognized revenue, and sustainable profit margins?
I am keeping a close eye on order fulfillment, customer demand, and transaction volume. The robotics industry holds immense potential, but ultimate success hinges on execution. 📈